Ignite Creation Date:
2024-05-05 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00018603
Status:
COMPLETED
Last Update Posted:
2009-01-21
First Post:
2001-07-03
Brief Title:
Guanfacine for the Treatment of Post Traumatic Stress Disorder PTSD
Sponsor:
US Department of Veterans Affairs
Organization:
VA Office of Research and Development
Study Overview
Official Title:
Guanfacine for the Treatment of PTSD
Status:
COMPLETED
Status Verified Date:
2004-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a double-blind placebo-controlled randomized study lasting 8 weeks Purpose of the study is two-fold first to use a pharmacological agent to treat symptoms of PTSD and second to explore neurobiological mechanisms of action of guanfacine
Detailed Description:
Subject population is comprised of 100 persons with PTSD 50 patients will receive guanfacine and 50 patients will receive a placebo Guanfacine is prescribed at 1 mgday and may be increased to 2 mgday Samples of plasma MHPG will be collected weekly Clinical ratings of PTSD anxiety and depression as well as vital signs will be assessed weekly Repeated measures analysis of variance will assess significance of main effect of drug time and drug by time
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None